Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEMULEN 1/50-21 vs LARIN 1/20
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
DEMULEN 1/50-21 is a combined oral contraceptive containing ethinyl estradiol and ethynodiol diacetate. Ethinyl estradiol and progestins inhibit gonadotropin release (FSH and LH) from the pituitary, suppressing ovulation. Progestins also increase cervical mucus viscosity and alter endometrial receptivity, impeding sperm penetration and implantation.
Combination estrogen-progestin contraceptive; suppresses gonadotropins (FSH, LH) via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation; increases cervical mucus viscosity, inhibiting sperm penetration; alters endometrial receptivity.
Prevention of pregnancy,Treatment of moderate acne vulgaris (off-label use)
Prevention of pregnancy,Oral contraceptive
1 tablet (ethinyl estradiol 50 mcg, norethindrone 1 mg) orally once daily for 21 days, followed by 7 days off.
One tablet (0.1 mg levonorgestrel/20 mcg ethinyl estradiol) orally once daily for 21 days followed by 7 placebo days.
Ethinylestradiol: 13 ± 3 h (biphasic; terminal phase used for dosing interval). Clinical context: steady-state achieved after ~3 days; missed dose may reduce contraceptive efficacy if >36 h.
Norethindrone: 7.6 hours (range 5-14); Ethinyl estradiol: 13.2 hours (range 8-20). Clinical context: Steady-state achieved within 5-10 days.
Ethinyl estradiol undergoes first-pass metabolism in the gut wall and liver, with hydroxylation by CYP3A4 and conjugation via glucuronidation and sulfation. Ethynodiol diacetate is rapidly deacetylated to norethindrone, which is metabolized by reduction and conjugation, with CYP3A4 as a minor pathway.
Ethinyl estradiol: primarily metabolized by CYP3A4; undergoes first-pass metabolism in gut and liver. Norethindrone: primarily metabolized by reduction and conjugation; substrate of CYP3A4.
Renal (approx. 50% as metabolites, <1% unchanged), fecal (approx. 40%, largely as ethinylestradiol conjugates), biliary (minor, enterohepatic recirculation of ethinylestradiol)
Approximately 60% renal (30% norethindrone, 30% ethinyl estradiol metabolites) and 40% fecal (biliary excretion of conjugates).
Ethinylestradiol: 97-98% bound to serum albumin (primarily) and SHBG; ethynodiol diacetate: >95% bound to albumin and SHBG.
Norethindrone: 61% (albumin, SHBG); Ethinyl estradiol: 97% (albumin).
Ethinylestradiol: 2.8-4.3 L/kg (extensive tissue distribution, including breast and reproductive tissues); ethynodiol: 1.5-2.0 L/kg.
Norethindrone: 3.8 L/kg; Ethinyl estradiol: 2.8 L/kg. Indicates extensive tissue distribution.
Oral: Ethinylestradiol 38-48% (first-pass metabolism); ethynodiol diacetate ~60% (rapid hydrolysis to active norethindrone).
Oral: Norethindrone 64% (first-pass metabolism); Ethinyl estradiol 38-48% (first-pass metabolism).
No dose adjustment required for mild-moderate renal impairment. Avoid use in severe renal impairment or dialysis due to potential fluid retention and electrolyte disturbances.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment (GFR <30 m L/min) due to potential fluid retention and metabolic acidosis.
Contraindicated in acute or chronic hepatic dysfunction, including Child-Pugh class A, B, or C. Use in mild hepatic impairment not recommended.
Contraindicated in acute hepatic disease, hepatic adenomas, or severe cirrhosis (Child-Pugh class C). No specific dose adjustments provided for mild to moderate impairment; use caution.
Not indicated for use before menarche. For post-menarcheal adolescents, same dosing as adults. Safety and efficacy established in post-pubertal females.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults: one tablet orally once daily for 21 days followed by 7 placebo days.
Not indicated after menopause. Risk of thromboembolic events outweighs benefits in women over 35 who smoke or have cardiovascular risk factors.
Not indicated for use after menopause. No specific dose adjustments in elderly; increased risk of thrombosis and hypoglycemia warrants caution.
Cigarette smoking increases the risk of serious cardiovascular events from oral contraceptive use. This risk increases with age and with the number of cigarettes smoked, and is quite marked in women over 35 years of age. Women who use oral contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age (especially >35 years) and with heavy smoking (≥15 cigarettes/day). Women who use combination hormonal contraceptives should not smoke.
Increased risk of thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking increases cardiovascular risk, especially in women over 35,Increased risk of hypertension, gallbladder disease, and hepatic neoplasia,Risk of retinal thrombosis; discontinue if unexplained vision loss occurs,May cause fluid retention; use with caution in conditions affected by fluid retention,May induce cholestatic jaundice; discontinue if jaundice develops,May cause carbohydrate and lipid metabolism changes
Thrombotic disorders: discontinue if thrombophlebitis, thromboembolic, or vascular events occur,Carcinoma risk: increased risk of breast cancer; cervical cancer association,Hepatic effects: acute liver disease, liver tumors,Elevated blood pressure,Gallbladder disease,Carbohydrate/lipid metabolic effects,Ocular lesions: retinal thrombosis; discontinue if unexplained vision loss,Hereditary angioedema exacerbation,Chloasma,Pregnancy: discontinue if pregnancy occurs
Known or suspected pregnancy,Current or past history of thrombophlebitis or thromboembolic disorders,Cerebrovascular or coronary artery disease,Known or suspected breast carcinoma,Endometrial carcinoma or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma,Active liver disease (e.g., acute viral hepatitis, decompensated cirrhosis),Hypersensitivity to any component
Thrombophlebitis or thromboembolic disorders,History of deep vein thrombosis or pulmonary embolism,Cerebrovascular or coronary artery disease,Known or suspected breast cancer,Endometrial or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Heavy smoking (≥15 cigarettes/day) in women >35 years
No specific food interactions. Oral contraceptives may increase caffeine levels; limit caffeine intake if side effects like jitteriness occur. Grapefruit and grapefruit juice do not significantly affect this medication.
Grapefruit and grapefruit juice may increase estrogen levels; limit intake. No other significant food interactions. Avoid St. John's wort (herbal supplement) as it reduces contraceptive efficacy. Alcohol may increase risk of liver toxicity; moderate consumption is generally acceptable.
First trimester: Use contraindicated due to increased risk of congenital anomalies, particularly cardiovascular defects and limb reduction defects, associated with sex hormones. Second and third trimesters: Avoid due to risk of fetal harm, including masculinization of female fetus with progestins; also associated with increased risk of neonatal jaundice and liver dysfunction.
LARIN 1/20 (norethindrone acetate/ethinyl estradiol) is contraindicated in pregnancy. First trimester: No increased risk of major birth defects from low-dose OCs in cohort studies, but an increased risk of cardiovascular malformations (e.g., VSD, TGA) and neural tube defects has been suggested in some studies; risk of oral cleft is not increased. Second/third trimesters: Use may increase risk of fetal hepatic adenoma, fetal feminization with androgenic progestins (norethindrone has minimal androgenicity), and potential for neonatal withdrawal bleeding or hormonal effects; no clear risk of pregnancy loss beyond baseline.
Small amounts of ethinyl estradiol and ethynodiol diacetate are excreted in breast milk. M/P ratio not established. Estrogen-progestin combinations may reduce milk production and alter milk composition; use during breastfeeding is generally not recommended. Consider alternative contraception.
Small amounts of ethinyl estradiol and norethindrone pass into breast milk; combined OCs are generally not recommended during breastfeeding, especially in early lactation, as they may reduce milk quantity and quality. M/P ratio: Not established for LARIN 1/20; ethinyl estradiol M/P ratio is ~0.2-0.4, norethindrone M/P ratio ~0.1. Infants exposed via milk show no significant adverse effects, but theoretical risks include jaundice, breast enlargement, and long-term carcinogenicity. Use of progestin-only contraceptives is preferred.
Not applicable as use is contraindicated during pregnancy. No pharmacokinetic studies have been conducted to recommend dose adjustments.
LARIN 1/20 is contraindicated in pregnancy; no dose adjustment recommended because drug should be discontinued immediately if pregnancy is detected. Pharmacokinetic changes in pregnancy (e.g., increased clearance, decreased SHBG, increased volume of distribution) would theoretically require higher doses if used, but use is not indicated. No standard dosing for use during gestation.
DEMULEN 1/50-21 is a monophasic oral contraceptive containing ethinyl estradiol 50 mcg and ethynodiol diacetate 1 mg. Use with caution in patients over 35 who smoke due to increased cardiovascular risk. Monitor for breakthrough bleeding, especially in the first three cycles. Consider drug interactions with rifampin, anticonvulsants, and broad-spectrum antibiotics. Administer at the same time daily to maintain efficacy. The 21-day regimen requires a 7-day pill-free interval. Instruct to start on first day of menses or first Sunday after onset.
LARIN 1/20 (norethindrone acetate 1 mg/ethinyl estradiol 20 mcg) has a low estrogen dose, which may reduce estrogen-related side effects but can increase breakthrough bleeding. It is a monophasic pill. Starting on the first day of menses provides immediate contraceptive protection. Caution in patients with migraine with aura or uncontrolled hypertension. Check for drug interactions with CYP3A4 inducers (e.g., rifampin, St. John's wort).
Take one tablet daily at the same time, starting on the first day of your menstrual period or the first Sunday after your period begins.,Swallow tablet whole with water, with or without food.,After finishing all 21 tablets, wait 7 days before starting a new pack. You will have a withdrawal bleed during this time.,If you miss a tablet by less than 12 hours, take it immediately. If more than 12 hours, take the missed tablet and use backup contraception for 7 days.,Seek emergency medical care for symptoms of blood clots (sudden severe headache, chest pain, shortness of breath, leg pain/swelling), stroke (sudden numbness/weakness, slurred speech), or liver problems (yellowing skin/eyes, dark urine).,Avoid smoking while taking this medication, especially if over age 35, due to increased risk of cardiovascular events.,Inform your healthcare provider about all other medications (including over-the-counter drugs, herbal supplements like St. John's Wort) as they may reduce contraceptive efficacy.,This medication does not protect against HIV or other sexually transmitted infections.
Take one pill daily at the same time; missing pills increases pregnancy risk.,If you miss a pill, follow the package instructions; use backup contraception if needed.,Common side effects include nausea, breast tenderness, and breakthrough bleeding, especially in the first few months.,Do not smoke while taking this medication, especially if over 35; smoking increases risk of serious cardiovascular events.,This pill does not protect against STIs; use condoms for protection.,Inform your healthcare provider of all medications and supplements you take, especially St. John's wort, antibiotics, and anticonvulsants.,Contact your doctor if you experience severe headache, chest pain, leg pain or swelling, sudden shortness of breath, or vision changes.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEMULEN 1/50-21 vs LARIN 1/20, answered by our medical review team.
DEMULEN 1/50-21 is a Combination Oral Contraceptive that works by DEMULEN 1/50-21 is a combined oral contraceptive containing ethinyl estradiol and ethynodiol diacetate. Ethinyl estradiol and progestins inhibit gonadotropin release (FSH and LH) from the pituitary, suppressing ovulation. Progestins also increase cervical mucus viscosity and alter endometrial receptivity, impeding sperm penetration and implantation.. LARIN 1/20 is a Combination Oral Contraceptive that works by Combination estrogen-progestin contraceptive; suppresses gonadotropins (FSH, LH) via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation; increases cervical mucus viscosity, inhibiting sperm penetration; alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEMULEN 1/50-21 and LARIN 1/20 depend on the specific clinical indication. These are both Combination Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEMULEN 1/50-21 is: 1 tablet (ethinyl estradiol 50 mcg, norethindrone 1 mg) orally once daily for 21 days, followed by 7 days off.. The standard adult dose of LARIN 1/20 is: One tablet (0.1 mg levonorgestrel/20 mcg ethinyl estradiol) orally once daily for 21 days followed by 7 placebo days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DEMULEN 1/50-21 and LARIN 1/20 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DEMULEN 1/50-21 is classified as Category C. First trimester: Use contraindicated due to increased risk of congenital anomalies, particularly cardiovascular defects and limb reduction defects, associated with sex hormones. Se. LARIN 1/20 is classified as Category C. LARIN 1/20 (norethindrone acetate/ethinyl estradiol) is contraindicated in pregnancy. First trimester: No increased risk of major birth defects from low-dose OCs in cohort studies,. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.